GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » 3-Year EBITDA Growth Rate

Virios Therapeutics (Virios Therapeutics) 3-Year EBITDA Growth Rate : 47.70% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics 3-Year EBITDA Growth Rate?

Virios Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was $-0.07.

During the past 3 years, the average EBITDA Per Share Growth Rate was 47.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Virios Therapeutics was 47.70% per year. The lowest was -66.60% per year. And the median was -35.10% per year.


Competitive Comparison of Virios Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Virios Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virios Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's 3-Year EBITDA Growth Rate falls into.



Virios Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Virios Therapeutics  (NAS:VIRI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Virios Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Virios Therapeutics (Virios Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009

Virios Therapeutics (Virios Therapeutics) Headlines

From GuruFocus

Virios Therapeutics Announces First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023